Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:17:14.805Z.
Consensus retrieved: 2026-10-06T13:12:08.482Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:17:14.805Z.
Quote observation: 2026-10-06T14:15:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 44fde230bfdd574c3cd4cd53b0628620ec84ec898484da9a9f15813d4ff0e801
Forward PE Ratio (N/A) = Dated Quote Price ($22.73) / Consensus Forward EPS ($-1.22)
FORWARD PE RATIO
N/A
OrthoPediatrics Corp.
Market Cap
$583.82M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| OrthoPediatrics Corp. (KIDS) | $583.82M | N/A |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $572.90M | N/A |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $598.37M | 2.97 |
| CorMedix Inc. (CRMD)vs › | $563.90M | 14.52 |
| Aquestive Therapeutics, Inc. (AQST)vs › | $563.35M | N/A |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $560.05M | N/A |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A |
| CytomX Therapeutics, Inc. (CTMX)vs › | $553.64M | N/A |
| AngioDynamics, Inc. (ANGO)vs › | $620.81M | N/A |
| Fulgent Genetics, Inc. (FLGT)vs › | $621.12M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $22.73, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.22 | $-1.24 – $-1.21 | 4 | n/m |
| 2027-12-31 | $-0.82 | $-0.85 – $-0.79 | 5 | n/m |
| 2028-12-31 | $-0.38 | $-1.13 – $0.35 | 4 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
